Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 6 | 0 | 6 |
| 1994 | 5 | 3 | 8 |
| 1995 | 7 | 2 | 9 |
| 1996 | 4 | 0 | 4 |
| 1997 | 4 | 0 | 4 |
| 1998 | 10 | 1 | 11 |
| 1999 | 4 | 0 | 4 |
| 2000 | 5 | 2 | 7 |
| 2001 | 6 | 2 | 8 |
| 2002 | 6 | 1 | 7 |
| 2003 | 17 | 1 | 18 |
| 2004 | 8 | 1 | 9 |
| 2005 | 13 | 5 | 18 |
| 2006 | 13 | 4 | 17 |
| 2007 | 19 | 2 | 21 |
| 2008 | 17 | 4 | 21 |
| 2009 | 16 | 3 | 19 |
| 2010 | 19 | 3 | 22 |
| 2011 | 37 | 4 | 41 |
| 2012 | 26 | 0 | 26 |
| 2013 | 33 | 1 | 34 |
| 2014 | 21 | 3 | 24 |
| 2015 | 45 | 2 | 47 |
| 2016 | 37 | 3 | 40 |
| 2017 | 32 | 2 | 34 |
| 2018 | 43 | 4 | 47 |
| 2019 | 44 | 3 | 47 |
| 2020 | 52 | 2 | 54 |
| 2021 | 46 | 3 | 49 |
| 2022 | 38 | 0 | 38 |
| 2023 | 28 | 0 | 28 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
-
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1260-1266.
-
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precis Oncol. 2023 09; 7:e2300118.
-
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. Clin Lung Cancer. 2023 11; 24(7):631-640.e2.
-
Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2023 11; 24(7):651-659.
-
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 09; 24(9):989-1001.
-
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 Jul 07; 13(7):1556-1571.
-
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096.
-
Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy? J Natl Cancer Inst. 2023 06 08; 115(6):605-607.
-
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 06; 11(6).